Overview

FIH (First in Human) Trial Evaluating Safety of TUM012 to Minimize Ischemic Reperfusion Injury in Kidney Transplantation

Status:
Not yet recruiting

Trial end date:
2023-03-03

Target enrollment:

Participant gender:

Summary

A first-in-human single center, randomized, double-blind, placebo-controlled trial, with primary objective to evaluate safety and tolerability of ex-vivo kidney allograft treatment with TUM012 to reduce ischemia-reperfusion injury in de novo kidney transplant recipients.

Phase:

Early Phase 1

Details

Lead Sponsor:

iCoat Medical AB

Collaborators:

CTC Clinical Trial Consultants AB
Region Skane